These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites. Potempa M; Lee SK; Kurt Yilmaz N; Nalivaika EA; Rogers A; Spielvogel E; Carter CW; Schiffer CA; Swanstrom R J Mol Biol; 2018 Dec; 430(24):5182-5195. PubMed ID: 30414407 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements. Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939 [TBL] [Abstract][Full Text] [Related]
6. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Tözsér J; Weber IT; Gustchina A; Bláha I; Copeland TD; Louis JM; Oroszlan S Biochemistry; 1992 May; 31(20):4793-800. PubMed ID: 1591240 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099 [TBL] [Abstract][Full Text] [Related]
8. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity. Tossi A; Antcheva N; Romeo D; Miertus S Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416 [TBL] [Abstract][Full Text] [Related]
9. Specificity mapping of HIV-1 protease by reduced bond inhibitors. Majer P; Urban J; Gregorová E; Konvalinka J; Novek P; Stehlíková J; Andreánsky M; Sedlácek J; Strop P Arch Biochem Biophys; 1993 Jul; 304(1):1-8. PubMed ID: 8323274 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538 [TBL] [Abstract][Full Text] [Related]
11. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363 [TBL] [Abstract][Full Text] [Related]
12. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; Bannow C; Reardon IM; Howe WJ; DeCamp DL; Craik CS; Heinrikson RL J Biol Chem; 1990 Aug; 265(24):14675-83. PubMed ID: 2201691 [TBL] [Abstract][Full Text] [Related]
13. Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24-15 using combinatorial chemistry. Jirácek J; Yiotakis A; Vincent B; Lecoq A; Nicolaou A; Checler F; Dive V J Biol Chem; 1995 Sep; 270(37):21701-6. PubMed ID: 7665587 [TBL] [Abstract][Full Text] [Related]
14. The evaluation of non-viral substrates of the HIV protease as leads in the design of inhibitors for AIDS therapy. Tomasselli AG; Hui JO; Sawyer TK; Thaisrivongs S; Hester JB; Heinrikson RL Adv Exp Med Biol; 1991; 306():469-82. PubMed ID: 1812744 [TBL] [Abstract][Full Text] [Related]
15. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures. Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407 [TBL] [Abstract][Full Text] [Related]
16. Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element. Raju B; Deshpande MS Biochem Biophys Res Commun; 1991 Oct; 180(1):181-6. PubMed ID: 1930214 [TBL] [Abstract][Full Text] [Related]
17. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609 [TBL] [Abstract][Full Text] [Related]